Pulmonary hypertension, which has around 500–1,000 new cases in the US each year, is currently managed with pharmaceutical agents. Image credit: Shutterstock/Design_Cells.

Aria CV has kicked off its ASPIRE PH trial and successfully implanted the first patient with its system to treat pulmonary hypertension.

The patient was implanted with Aria CV’s Gen 2 pulmonary hypertension system – a gas-filled balloon administered percutaneously.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Pulmonary hypertension is characterised by high blood pressure in lung arteries, which causes the heart to work harder to counteract the pressure, which can lead to right heart failure.

Aria CV’s device, which was granted US Food and Drug Administration breakthrough designation in 2020, aims to reduce cardiac workload. It is implanted in the main pulmonary artery and designed to restore the vessel’s healthy status, thereby mitigating right heart failure. According to the company, the device is driven by the heart and has no battery, pump or electronics.

The ASPIRE PH trial (NCT04555161) is an early feasibility study assessing the safety and performance of Aria CV’s system. The trial aims to enrol 30 participants with pulmonary hypertension, according to a ClinicalTrials.gov entry. The primary endpoint is the incidence of serious adverse events related to the device or the procedure through 30 days.

See Also:

Dr Ashwin Ravichandran, who helped perform the first procedure, said: “[This device] offers an alternative treatment for patients who remain significantly impacted by right heart dysfunction related to pulmonary hypertension, which has limited approved therapy options.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pulmonary hypertension, which has around 500–1,000 new cases in the US each year, is a relatively untapped therapy space in medtech. Currently, the disease is managed by a plethora of pharmaceutical products including endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclins.

The study is being funded by a Series B financing round from 2020, in which the company raised $31m.

Also in the space is Gradient Denervation Technologies, which is currently conducting a clinical study for an implanted device. The Paris-based company completed the first-in-human procedure in June 2023.

The global cardiovascular device market was estimated to be worth nearly $60bn in 2023. It is forecast to grow to more than $86bn by 2030, according to a report by GlobalData.